iRhythm Technologies, Inc. (NASDAQ:IRTC) Stock Holdings Boosted by Barclays PLC

Barclays PLC lifted its stake in iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 215,511 shares of the company's stock after buying an additional 6,264 shares during the period. Barclays PLC owned approximately 0.69% of iRhythm Technologies worth $19,434,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. R Squared Ltd acquired a new stake in iRhythm Technologies in the fourth quarter valued at approximately $45,000. Van ECK Associates Corp grew its holdings in iRhythm Technologies by 41.3% during the 4th quarter. Van ECK Associates Corp now owns 554 shares of the company's stock valued at $50,000 after purchasing an additional 162 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in iRhythm Technologies by 166.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,037 shares of the company's stock worth $94,000 after buying an additional 648 shares during the period. KBC Group NV boosted its position in iRhythm Technologies by 45.1% in the 4th quarter. KBC Group NV now owns 1,319 shares of the company's stock valued at $119,000 after buying an additional 410 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of iRhythm Technologies during the third quarter valued at about $119,000.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Wells Fargo & Company boosted their price target on iRhythm Technologies from $86.00 to $104.00 and gave the stock an "equal weight" rating in a research note on Friday, February 21st. Needham & Company LLC lifted their price target on shares of iRhythm Technologies from $125.00 to $138.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. StockNews.com upgraded shares of iRhythm Technologies from a "sell" rating to a "hold" rating in a research note on Monday, February 24th. Oppenheimer boosted their target price on shares of iRhythm Technologies from $105.00 to $120.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 8th. Finally, The Goldman Sachs Group increased their price target on shares of iRhythm Technologies from $91.00 to $124.00 and gave the stock a "neutral" rating in a research report on Monday, February 24th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $119.73.

iRhythm Technologies Stock Performance

Shares of NASDAQ IRTC traded up $2.18 during mid-day trading on Thursday, hitting $104.82. The company had a trading volume of 155,403 shares, compared to its average volume of 459,067. iRhythm Technologies, Inc. has a 12 month low of $55.92 and a 12 month high of $128.52. The stock has a market cap of $3.35 billion, a price-to-earnings ratio of -28.80 and a beta of 1.45. The company has a debt-to-equity ratio of 9.00, a current ratio of 6.27 and a quick ratio of 6.12. The firm's 50 day simple moving average is $104.76 and its two-hundred day simple moving average is $93.96.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.30. The company had revenue of $164.33 million for the quarter, compared to analysts' expectations of $158.30 million. iRhythm Technologies had a negative return on equity of 118.83% and a negative net margin of 19.14%. As a group, equities research analysts forecast that iRhythm Technologies, Inc. will post -1.98 earnings per share for the current year.

About iRhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.